Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Genomelink
AddedMar 17, 2024
UpdatedJul 1, 2026
Genomelink

Genomelink

Seed

Unlock unique DNA apps at Genomelink, with global ancestry and body/mind traits analysis. Backed by top investors and experts.

Founded
2017
Accelerator
Y Combinator logoY CombinatorS21
Overview
Compare
Fundraising
Employees
Website

Genomelink, founded by experts from M3, Inc., MyCode, and Sony, is a DNA App Store that allows users to transfer their DNA data from companies like 23andMe and Ancestry to unlock a variety of unique applications. The company's core mission is to provide deeper insights into global ancestry and a broader analysis of body and mind traits than what is typically available from other genetic testing services. Genomelink aims to empower individuals with more comprehensive genetic information and personalized tools for understanding their DNA.

Notable figures affiliated with Genomelink include Tomo from M3, Inc., Yuta from MyCode, and Ken from Sony, who bring extensive experience in medical platforms, consumer genetic testing, and bioinformatics. The company has garnered support from top investors and has achieved significant milestones in expanding the accessibility and depth of genetic data analysis. Genomelink's impact lies in its ability to offer users a more detailed and diverse understanding of their genetic makeup, enhancing the value derived from their existing DNA data.

Genomelink - Quick Facts

When was Genomelink founded?

Genomelink was founded in 2017.

When was Genomelink's last funding round?

Genomelink's most recent funding round was for $125k (USD) in January 2021.

How much has Genomelink raised to-date?

As of Jan 1, 2021, Genomelink has raised a total of $125k (USD).

How many employees does Genomelink have?

Genomelink has 15 employees as of Feb 16, 2024.

Genomelink - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Transactional
Customer
  • Consumers
Main Product
  • DNA Analysis
Tags
  • Biotech
  • Data Information
  • GenAI